Default company panoramic image
Logo

JANUS DEVELOPMENT S.L

Biomedical project incubator with the mission of transforming early stage biomedical knowledge into social and economic value.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Barcelona Wine Bar & Restaurant, Temple Street, New Haven, CT, US
  • Currency EUR
  • Founded March 2009
  • Employees 6
  • Website janusdevelopments.com

Company Summary

Janus acquires development and commercialization rights on university and research institute’s patents, invests in the early stages of product development and subsequently licenses these projects either to larger companies able to continue the development and take the products to market, or to Janus spin-offs able to attract VC investment. Revenues are obtained from royalties from out-licensed projects or from trade sale of portfolio companies.

Team

  • Default avatar
    Luis Ruiz Avila
    Dr

    PhD, 10 years of academic research experience, 4 years project management experience and corporate business development, 7 years as CEO in the biotech sector from the beginning up to the stage of development (Advancell and ERABiotech.) He is CEO of Janus and is responsible for business development (relationship with potential customers and generating new opportunities for in-licensing) and interim management.

  • Default avatar
    Maribel Berges Fraile
    Mrs

    Chemical Engineer, MBA IESE (Class of 2000), technical expertise in the pharmaceutical industry (Almirall), 7 years in the Fundació Bosch i Gimpera Foundation, Office of Technology Transfer at the University of Barcelona, the last 4 years as Area manager, responsible for licensing technologies and support spin-offs from the UB. She is the CFO, and responsible for economic evaluation of new projects, consultancy and interim management.

  • Default avatar
    Ramon Bosser Artal
    Dr.

    7 years in R&D experience in vitro diagnostics, 6 years basic research and teaching, with more than 13 years experience in project management and planning in the pharmaceutical industry, from preclinical stage to commercialization (Almirall). He is the COO of Janus, responsible for development of projects: assessment, planning and implementation of projects and interim management and consulting services.

  • Default avatar
    Richard Davenport Gill
    Dr

    Dr. Gill has over 28 years of strategic
    management, research, and technology commercialization experience in the life sciences industry, with key top executive roles in Truetouch, ProNAi Therapeutics,Signet
    Laboratories, AnVil, ActiveCyte, Genome Therapeutics
    Corp; now Oscient Pharmaceuticals (NASDAQ: OSCI), and BTG International, Inc., a subsidiary of BTG plc (LSE: BTG plc (LSE: BGC). He serves as non executive director in the Janus Board

Advisors

  • Default avatar
    Manubens y Asociados
    Lawyer
    Unconfirmed
    Default avatar
    BDO
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Grupo Ferrer Internacional
    Unconfirmed
    Default avatar
    Enantia S.L.
    Unconfirmed
    Default avatar
    Catalunya Caixa
    Unconfirmed